Athene Holding Ltd.ATHNYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

$83.33

-0.69%(-0.58)

Open

$83.29

Previous Close

$83.91

High

$84.32

Low

$82.17

$83.91

Volume

3,498,864

Avg Volume

1,193,139

Previous Volume

3,498,864

52 Week High

$91.26

52 Week Low

$40.21

Market Cap

$19.79B

P/E Ratio

4.42

Extended Price

$83.33

Extended Change

+0.00

Extended Change %

+0.00%

Alerts

Want to monitor ATH?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Create free account to monitor ATH

Key Statistics

About

Apollo is a leading global investment manager with assets under management of approximately $455 billion as of December 31, 2020 in credit, private equity, and real assets funds.

Sector

Finance and Insurance

Industry

Direct Life Insurance Carriers

CEO

James Belardi

www.athene.com →

News

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

prnewswire.com

Musk and Ryanair CEO clash over cost of Starlink Wi-Fi on planes

reuters.com

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

seekingalpha.com

Can IREN's Vertically Integrated AI Cloud Platform Lift Profitability?

zacks.com

IREN or HUT: Which Bitcoin Infrastructure Stock Should You Bet On?

zacks.com

Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Rebounds As Traders Focus On Supply Risks

fxempire.com

Are Early-Season Metrics Signaling Challenges for Vail Resorts?

zacks.com

Genmab's blood cancer drug fails main goal in late-stage study

reuters.com

Federal Signal Completes Acquisition of Mega Corp.

prnewswire.com

Incyte: Buy For The Turnaround, Stay For The Pipeline

seekingalpha.com

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

businesswire.com

International oil companies push for quick reforms in Venezuela to give them control over oil exports

reuters.com

Reasons Why You Should Retain MARA Stock in Your Portfolio

zacks.com

Why Clorox Stock Remains Worth Holding in Your Portfolio Now?

zacks.com

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

globenewswire.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

$83.33

Alerts

Key Statistics

About

News

Intel: Big Day

DexCom Stock Declines Following Strong Preliminary Q4 Results

Here is Why Growth Investors Should Buy Universal Health Services (UHS) Now

3 Reasons Growth Investors Will Love Global Payments (GPN)

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Musk and Ryanair CEO clash over cost of Starlink Wi-Fi on planes

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Can IREN's Vertically Integrated AI Cloud Platform Lift Profitability?

IREN or HUT: Which Bitcoin Infrastructure Stock Should You Bet On?

Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Rebounds As Traders Focus On Supply Risks

Are Early-Season Metrics Signaling Challenges for Vail Resorts?

Genmab's blood cancer drug fails main goal in late-stage study

Federal Signal Completes Acquisition of Mega Corp.

Incyte: Buy For The Turnaround, Stay For The Pipeline

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

International oil companies push for quick reforms in Venezuela to give them control over oil exports

Reasons Why You Should Retain MARA Stock in Your Portfolio

Why Clorox Stock Remains Worth Holding in Your Portfolio Now?

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Explore More

Intel: Big Day

DexCom Stock Declines Following Strong Preliminary Q4 Results

Here is Why Growth Investors Should Buy Universal Health Services (UHS) Now

3 Reasons Growth Investors Will Love Global Payments (GPN)

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Musk and Ryanair CEO clash over cost of Starlink Wi-Fi on planes

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Can IREN's Vertically Integrated AI Cloud Platform Lift Profitability?

IREN or HUT: Which Bitcoin Infrastructure Stock Should You Bet On?

Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Rebounds As Traders Focus On Supply Risks

Are Early-Season Metrics Signaling Challenges for Vail Resorts?

Genmab's blood cancer drug fails main goal in late-stage study

Federal Signal Completes Acquisition of Mega Corp.

Incyte: Buy For The Turnaround, Stay For The Pipeline

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

International oil companies push for quick reforms in Venezuela to give them control over oil exports

Reasons Why You Should Retain MARA Stock in Your Portfolio

Why Clorox Stock Remains Worth Holding in Your Portfolio Now?

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

$83.33